The world needs new medicines and drug developers are racing to bring promising molecules to the market. However, drug development programs stall when:

???????? - Physicochemical properties of API form and formulation are uncertain

???????? - Lead compounds require quantifiable comparison

???????? - Form and formulation guesswork cause incoherent tox exposures

?

?

From lead optimization to First in Human (FIH), programs are at risk of hitting significant speed bumps if the physicochemical risks for API form and formulation are never evaluated.

?

Innovators need a strategic and cohesive approach to move their molecule to medicine.

?

Molecule to Medicine

The Mol2Med? Developability Assessment is a dynamic, fit-for-purpose service that helps drug developers achieve a comprehensive understanding of their molecule's potential for development.

With as little as 500mg of API and 4 weeks, Crystal Pharmatech offers a smarter path forward by:

???????? - Determining the key physicochemical properties of your compound(s)

???????? - Benchmarking according to industry standards

???????? - Providing a high-level approach for achieving most probable success in GLP Tox and FIH